世界のオルニチン-トランスカルバミラーゼ欠損症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Ornithine-Transcarbamylase Deficiency Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4629 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、オルニチン-トランスカルバミラーゼ欠損症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（DTX-301、SEL-313、SHP-641、PRX-OTC、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・オルニチン-トランスカルバミラーゼ欠損症の市場動向 ・企業の競争状況、市場シェア ・オルニチン-トランスカルバミラーゼ欠損症の種類別市場規模と予測2016-2027（DTX-301、SEL-313、SHP-641、PRX-OTC、その他） ・オルニチン-トランスカルバミラーゼ欠損症の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・オルニチン-トランスカルバミラーゼ欠損症の北米市場規模2016-2027（アメリカ、カナダ） ・オルニチン-トランスカルバミラーゼ欠損症の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・オルニチン-トランスカルバミラーゼ欠損症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・オルニチン-トランスカルバミラーゼ欠損症の中南米市場規模2016-2027（メキシコ、ブラジル） ・オルニチン-トランスカルバミラーゼ欠損症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Lucane Pharma SA、PhaseRx Inc、Promethera Biosciences SA、Selecta Biosciences Inc、Translate Bio Inc、Ultragenyx Pharmaceutical Inc、Unicyte AG） ・結論

Market Analysis and Insights: Global Ornithine-Transcarbamylase Deficiency Market
The global Ornithine-Transcarbamylase Deficiency market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Ornithine-Transcarbamylase Deficiency market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Ornithine-Transcarbamylase Deficiency market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Ornithine-Transcarbamylase Deficiency market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Ornithine-Transcarbamylase Deficiency market.

Global Ornithine-Transcarbamylase Deficiency Scope and Market Size
Ornithine-Transcarbamylase Deficiency market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Ornithine-Transcarbamylase Deficiency market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
DTX-301
SEL-313
SHP-641
PRX-OTC
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Lucane Pharma SA
PhaseRx Inc
Promethera Biosciences SA
Selecta Biosciences Inc
Translate Bio Inc
Ultragenyx Pharmaceutical Inc
Unicyte AG

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 DTX-301
1.2.3 SEL-313
1.2.4 SHP-641
1.2.5 PRX-OTC
1.2.6 Others
1.3 Market by Application
1.3.1 Global Ornithine-Transcarbamylase Deficiency Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Ornithine-Transcarbamylase Deficiency Market Perspective (2016-2027)
2.2 Ornithine-Transcarbamylase Deficiency Growth Trends by Regions
2.2.1 Ornithine-Transcarbamylase Deficiency Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Ornithine-Transcarbamylase Deficiency Historic Market Share by Regions (2016-2021)
2.2.3 Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Regions (2022-2027)
2.3 Ornithine-Transcarbamylase Deficiency Industry Dynamic
2.3.1 Ornithine-Transcarbamylase Deficiency Market Trends
2.3.2 Ornithine-Transcarbamylase Deficiency Market Drivers
2.3.3 Ornithine-Transcarbamylase Deficiency Market Challenges
2.3.4 Ornithine-Transcarbamylase Deficiency Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Ornithine-Transcarbamylase Deficiency Players by Revenue
3.1.1 Global Top Ornithine-Transcarbamylase Deficiency Players by Revenue (2016-2021)
3.1.2 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Players (2016-2021)
3.2 Global Ornithine-Transcarbamylase Deficiency Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Ornithine-Transcarbamylase Deficiency Revenue
3.4 Global Ornithine-Transcarbamylase Deficiency Market Concentration Ratio
3.4.1 Global Ornithine-Transcarbamylase Deficiency Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ornithine-Transcarbamylase Deficiency Revenue in 2020
3.5 Ornithine-Transcarbamylase Deficiency Key Players Head office and Area Served
3.6 Key Players Ornithine-Transcarbamylase Deficiency Product Solution and Service
3.7 Date of Enter into Ornithine-Transcarbamylase Deficiency Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Ornithine-Transcarbamylase Deficiency Breakdown Data by Type
4.1 Global Ornithine-Transcarbamylase Deficiency Historic Market Size by Type (2016-2021)
4.2 Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Type (2022-2027)

5 Ornithine-Transcarbamylase Deficiency Breakdown Data by Application
5.1 Global Ornithine-Transcarbamylase Deficiency Historic Market Size by Application (2016-2021)
5.2 Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Ornithine-Transcarbamylase Deficiency Market Size (2016-2027)
6.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Type
6.2.1 North America Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021)
6.2.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027)
6.2.3 North America Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2027)
6.3 North America Ornithine-Transcarbamylase Deficiency Market Size by Application
6.3.1 North America Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021)
6.3.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027)
6.3.3 North America Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2027)
6.4 North America Ornithine-Transcarbamylase Deficiency Market Size by Country
6.4.1 North America Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021)
6.4.2 North America Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Ornithine-Transcarbamylase Deficiency Market Size (2016-2027)
7.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Type
7.2.1 Europe Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021)
7.2.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027)
7.2.3 Europe Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2027)
7.3 Europe Ornithine-Transcarbamylase Deficiency Market Size by Application
7.3.1 Europe Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021)
7.3.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027)
7.3.3 Europe Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2027)
7.4 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country
7.4.1 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021)
7.4.2 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size (2016-2027)
8.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Type
8.2.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2027)
8.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Application
8.3.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2027)
8.4 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Region
8.4.1 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Ornithine-Transcarbamylase Deficiency Market Size (2016-2027)
9.2 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type
9.2.1 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021)
9.2.2 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027)
9.2.3 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2027)
9.3 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application
9.3.1 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021)
9.3.2 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027)
9.3.3 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2027)
9.4 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country
9.4.1 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021)
9.4.2 Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size (2016-2027)
10.2 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Type
10.2.1 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2027)
10.3 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Application
10.3.1 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2027)
10.4 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Country
10.4.1 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Lucane Pharma SA
11.1.1 Lucane Pharma SA Company Details
11.1.2 Lucane Pharma SA Business Overview
11.1.3 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Introduction
11.1.4 Lucane Pharma SA Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.1.5 Lucane Pharma SA Recent Development
11.2 PhaseRx Inc
11.2.1 PhaseRx Inc Company Details
11.2.2 PhaseRx Inc Business Overview
11.2.3 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Introduction
11.2.4 PhaseRx Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.2.5 PhaseRx Inc Recent Development
11.3 Promethera Biosciences SA
11.3.1 Promethera Biosciences SA Company Details
11.3.2 Promethera Biosciences SA Business Overview
11.3.3 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Introduction
11.3.4 Promethera Biosciences SA Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.3.5 Promethera Biosciences SA Recent Development
11.4 Selecta Biosciences Inc
11.4.1 Selecta Biosciences Inc Company Details
11.4.2 Selecta Biosciences Inc Business Overview
11.4.3 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Introduction
11.4.4 Selecta Biosciences Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.4.5 Selecta Biosciences Inc Recent Development
11.5 Translate Bio Inc
11.5.1 Translate Bio Inc Company Details
11.5.2 Translate Bio Inc Business Overview
11.5.3 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Introduction
11.5.4 Translate Bio Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.5.5 Translate Bio Inc Recent Development
11.6 Ultragenyx Pharmaceutical Inc
11.6.1 Ultragenyx Pharmaceutical Inc Company Details
11.6.2 Ultragenyx Pharmaceutical Inc Business Overview
11.6.3 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Introduction
11.6.4 Ultragenyx Pharmaceutical Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.6.5 Ultragenyx Pharmaceutical Inc Recent Development
11.7 Unicyte AG
11.7.1 Unicyte AG Company Details
11.7.2 Unicyte AG Business Overview
11.7.3 Unicyte AG Ornithine-Transcarbamylase Deficiency Introduction
11.7.4 Unicyte AG Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
11.7.5 Unicyte AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Ornithine-Transcarbamylase Deficiency Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of DTX-301
Table 3. Key Players of SEL-313
Table 4. Key Players of SHP-641
Table 5. Key Players of PRX-OTC
Table 6. Key Players of Others
Table 7. Global Ornithine-Transcarbamylase Deficiency Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Ornithine-Transcarbamylase Deficiency Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Ornithine-Transcarbamylase Deficiency Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Ornithine-Transcarbamylase Deficiency Market Share by Regions (2016-2021)
Table 11. Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Ornithine-Transcarbamylase Deficiency Market Share by Regions (2022-2027)
Table 13. Ornithine-Transcarbamylase Deficiency Market Trends
Table 14. Ornithine-Transcarbamylase Deficiency Market Drivers
Table 15. Ornithine-Transcarbamylase Deficiency Market Challenges
Table 16. Ornithine-Transcarbamylase Deficiency Market Restraints
Table 17. Global Ornithine-Transcarbamylase Deficiency Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Ornithine-Transcarbamylase Deficiency Market Share by Players (2016-2021)
Table 19. Global Top Ornithine-Transcarbamylase Deficiency Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ornithine-Transcarbamylase Deficiency as of 2020)
Table 20. Ranking of Global Top Ornithine-Transcarbamylase Deficiency Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Ornithine-Transcarbamylase Deficiency Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Ornithine-Transcarbamylase Deficiency Product Solution and Service
Table 24. Date of Enter into Ornithine-Transcarbamylase Deficiency Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2016-2021)
Table 28. Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Ornithine-Transcarbamylase Deficiency Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2016-2021)
Table 32. Global Ornithine-Transcarbamylase Deficiency Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size by Country (2022-2027) & (US$ Million)
Table 64. Lucane Pharma SA Company Details
Table 65. Lucane Pharma SA Business Overview
Table 66. Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Product
Table 67. Lucane Pharma SA Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 68. Lucane Pharma SA Recent Development
Table 69. PhaseRx Inc Company Details
Table 70. PhaseRx Inc Business Overview
Table 71. PhaseRx Inc Ornithine-Transcarbamylase Deficiency Product
Table 72. PhaseRx Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 73. PhaseRx Inc Recent Development
Table 74. Promethera Biosciences SA Company Details
Table 75. Promethera Biosciences SA Business Overview
Table 76. Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Product
Table 77. Promethera Biosciences SA Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 78. Promethera Biosciences SA Recent Development
Table 79. Selecta Biosciences Inc Company Details
Table 80. Selecta Biosciences Inc Business Overview
Table 81. Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Product
Table 82. Selecta Biosciences Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 83. Selecta Biosciences Inc Recent Development
Table 84. Translate Bio Inc Company Details
Table 85. Translate Bio Inc Business Overview
Table 86. Translate Bio Inc Ornithine-Transcarbamylase Deficiency Product
Table 87. Translate Bio Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 88. Translate Bio Inc Recent Development
Table 89. Ultragenyx Pharmaceutical Inc Company Details
Table 90. Ultragenyx Pharmaceutical Inc Business Overview
Table 91. Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Product
Table 92. Ultragenyx Pharmaceutical Inc Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 93. Ultragenyx Pharmaceutical Inc Recent Development
Table 94. Unicyte AG Company Details
Table 95. Unicyte AG Business Overview
Table 96. Unicyte AG Ornithine-Transcarbamylase Deficiency Product
Table 97. Unicyte AG Revenue in Ornithine-Transcarbamylase Deficiency Business (2016-2021) & (US$ Million)
Table 98. Unicyte AG Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ornithine-Transcarbamylase Deficiency Market Share by Type: 2020 VS 2027
Figure 2. DTX-301 Features
Figure 3. SEL-313 Features
Figure 4. SHP-641 Features
Figure 5. PRX-OTC Features
Figure 6. Others Features
Figure 7. Global Ornithine-Transcarbamylase Deficiency Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Ornithine-Transcarbamylase Deficiency Report Years Considered
Figure 12. Global Ornithine-Transcarbamylase Deficiency Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Ornithine-Transcarbamylase Deficiency Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Ornithine-Transcarbamylase Deficiency Market Share by Regions: 2020 VS 2027
Figure 15. Global Ornithine-Transcarbamylase Deficiency Market Share by Regions (2022-2027)
Figure 16. Global Ornithine-Transcarbamylase Deficiency Market Share by Players in 2020
Figure 17. Global Top Ornithine-Transcarbamylase Deficiency Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ornithine-Transcarbamylase Deficiency as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Ornithine-Transcarbamylase Deficiency Revenue in 2020
Figure 19. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2016-2021)
Figure 20. Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2022-2027)
Figure 21. North America Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Ornithine-Transcarbamylase Deficiency Market Share by Type (2016-2027)
Figure 23. North America Ornithine-Transcarbamylase Deficiency Market Share by Application (2016-2027)
Figure 24. North America Ornithine-Transcarbamylase Deficiency Market Share by Country (2016-2027)
Figure 25. United States Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Ornithine-Transcarbamylase Deficiency Market Share by Type (2016-2027)
Figure 29. Europe Ornithine-Transcarbamylase Deficiency Market Share by Application (2016-2027)
Figure 30. Europe Ornithine-Transcarbamylase Deficiency Market Share by Country (2016-2027)
Figure 31. Germany Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Ornithine-Transcarbamylase Deficiency Market Share by Region (2016-2027)
Figure 41. China Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Ornithine-Transcarbamylase Deficiency Market Share by Type (2016-2027)
Figure 49. Latin America Ornithine-Transcarbamylase Deficiency Market Share by Application (2016-2027)
Figure 50. Latin America Ornithine-Transcarbamylase Deficiency Market Share by Country (2016-2027)
Figure 51. Mexico Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Ornithine-Transcarbamylase Deficiency Market Share by Country (2016-2027)
Figure 57. Turkey Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Ornithine-Transcarbamylase Deficiency Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Lucane Pharma SA Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 61. PhaseRx Inc Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 62. Promethera Biosciences SA Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 63. Selecta Biosciences Inc Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 64. Translate Bio Inc Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 65. Ultragenyx Pharmaceutical Inc Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 66. Unicyte AG Revenue Growth Rate in Ornithine-Transcarbamylase Deficiency Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---